Rutgers Cancer Institute of New Jersey ( Site 0071) — New Brunswick, New Jersey

Rutgers Cancer Institute of New Jersey ( Site 0071) is a clinical research site located in New Brunswick, New Jersey, United States 08901.

Crixeo Health Trust Score: 56/100 (POOR). This profile has not yet been claimed by the site owner.

Rutgers Cancer Institute of New Jersey ( Site 0071) has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer.

Sponsors: Merck Sharp & Dohme LLC.

Sponsor Feasibility Report

Trust Score: 56/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Rutgers Cancer Institute of New Jersey ( Site 0071)?

Rutgers Cancer Institute of New Jersey ( Site 0071) has a Crixeo Trust Score of 56/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Rutgers Cancer Institute of New Jersey ( Site 0071) conducted?

Rutgers Cancer Institute of New Jersey ( Site 0071) has 1 clinical trials on record, with 1 currently active. Their work covers Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer.

Is Rutgers Cancer Institute of New Jersey ( Site 0071) accredited by Crixeo Health?

Rutgers Cancer Institute of New Jersey ( Site 0071) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Rutgers Cancer Institute of New Jersey ( Site 0071)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.